CA2103258A1 - Cytokine receptor targeted molecules for treatment of neoplastic cell growth - Google Patents

Cytokine receptor targeted molecules for treatment of neoplastic cell growth

Info

Publication number
CA2103258A1
CA2103258A1 CA002103258A CA2103258A CA2103258A1 CA 2103258 A1 CA2103258 A1 CA 2103258A1 CA 002103258 A CA002103258 A CA 002103258A CA 2103258 A CA2103258 A CA 2103258A CA 2103258 A1 CA2103258 A1 CA 2103258A1
Authority
CA
Canada
Prior art keywords
receptor
molecule
interleukin
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002103258A
Other languages
English (en)
French (fr)
Inventor
Cory A. Waters
Louis R. Poisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2103258A1 publication Critical patent/CA2103258A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002103258A 1991-05-17 1992-05-15 Cytokine receptor targeted molecules for treatment of neoplastic cell growth Abandoned CA2103258A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70193291A 1991-05-17 1991-05-17
US701,932 1991-05-17

Publications (1)

Publication Number Publication Date
CA2103258A1 true CA2103258A1 (en) 1992-11-18

Family

ID=24819258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002103258A Abandoned CA2103258A1 (en) 1991-05-17 1992-05-15 Cytokine receptor targeted molecules for treatment of neoplastic cell growth

Country Status (4)

Country Link
EP (1) EP0584251A4 (de)
JP (1) JPH06507900A (de)
CA (1) CA2103258A1 (de)
WO (1) WO1992020364A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800829B2 (de) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
WO2000074724A2 (en) * 1999-06-03 2000-12-14 Bioinnovation Limited Conjugates comprising cytokines and nucleic acids for treating proliferating cells
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
NZ234674A (en) * 1989-08-02 1992-02-25 Seragen Inc Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
CA2083487A1 (en) * 1990-06-13 1991-12-14 John R. Murphy Chimeric toxins with improved inter-domain geometry

Also Published As

Publication number Publication date
EP0584251A4 (de) 1995-08-02
JPH06507900A (ja) 1994-09-08
EP0584251A1 (de) 1994-03-02
WO1992020364A1 (en) 1992-11-26

Similar Documents

Publication Publication Date Title
DK173301B1 (da) Rekombinant pseudomonas exotoxin med modifikation i receptor bindingsdomænet Ia, target bærer-toxin konjugat, immunotoxiner
US5326559A (en) Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
Waters et al. Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells
CA2104958A1 (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
KR100386171B1 (ko) 면역접합체ii
EP1499730B1 (de) Immunokonjugate zur behandlung von tumoren
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
Terenzi et al. Anti‐CD30 (BER‐H2) immunotoxins containing the type‐1 ribosome‐inactivating proteins momordin and PAP‐S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice
WO1993015766A1 (en) Desensitization to specific allergens
Frankel et al. Immunotoxin therapy of hematologic malignancies
Lappi et al. The basic fibroblast growth factor‐saporin mitotoxin acts through the basic fibroblast growth factor receptor
AU665763B2 (en) Interleukin receptor targeted molecules for treatment of inflammatory arthritis
US5571507A (en) Methods of treating diabetes
CA2103258A1 (en) Cytokine receptor targeted molecules for treatment of neoplastic cell growth
Oeltmann et al. Advances in immunotoxins 1
Bendel et al. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor
Frankel et al. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor
vander Spek et al. Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease
AU705327B2 (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
WO1993025228A1 (en) Cytotoxins specific for gm-csf receptor-bearing cells
AU4016099A (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
Chan Diphtheria toxin based fusion toxins specifically targeting the murine granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors on tumor cells and bone marrow progenitor cells
FitzGerald et al. Recombinant Toxins Directed to Cytokine and Growth Factor Receptors
HK1072443B (en) Immunoconjugates for the treatment of tumours

Legal Events

Date Code Title Description
FZDE Discontinued